Welcome to our dedicated page for Repare Therapeutics SEC filings (Ticker: RPTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Repare Therapeutics Inc. (RPTX) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including Form 8-K reports that describe material events and corporate transactions. Repare’s common shares are registered under Section 12(b) of the Securities Exchange Act of 1934 and trade on The Nasdaq Stock Market LLC under the symbol RPTX, as reflected in its filings. These documents offer insight into the company’s precision oncology business, strategic agreements, and planned change in corporate structure.
Recent Form 8-K filings detail key developments such as the arrangement agreement with XenoTherapeutics, Inc. and Xeno Acquisition Corp., under which Xeno will acquire all issued and outstanding common shares of Repare through a court-approved plan of arrangement under the Business Corporations Act (Québec). The November 17, 2025 8-K describes the transaction terms, including a cash amount per share based on closing net cash and the issuance of non-transferable contingent value rights (CVRs) that entitle holders to potential future cash payments tied to specified receivables, partnerships with Bristol-Myers Squibb, Debiopharm and DCx Biotherapeutics, and licensing or disposition of product candidates and intellectual property.
Other 8-K filings referenced in 2025 address topics such as quarterly financial results, executive compensation and severance arrangements, and scientific and clinical communications, including the availability of abstracts related to the Phase 1 LIONS trial of RP-1664. These filings complement Repare’s press releases by providing formal regulatory descriptions of material agreements, voting and support arrangements with directors and officers, and conditions to closing for the Xeno transaction.
On Stock Titan, users can review these SEC filings alongside AI-powered summaries that explain complex sections, highlight the practical implications of items such as CVR structures, termination fees or voting thresholds, and help interpret how agreements and disclosures relate to Repare’s precision oncology programs. The page also serves as a reference point for tracking Repare’s transition from a Nasdaq-listed issuer toward becoming a privately held company, as described in its public filings and transaction announcements.
Repare Therapeutics Inc. completed its previously announced acquisition by XenoTherapeutics’ wholly owned subsidiary, Xeno Acquisition Corp., resulting in a change of control and Repare becoming a wholly owned subsidiary. Shareholders received approximately US$2.20 in cash per common share, plus one non-transferable contingent value right (CVR) per share for potential future cash payments under a CVR agreement.
In connection with the closing, Repare requested that Nasdaq suspend trading of its common shares after January 28, 2026 and file Form 25 to delist and deregister the shares. The purchaser intends to file Form 15 to terminate registration and suspend Exchange Act reporting, and the company has applied to cease to be a reporting issuer in Québec. All Repare directors resigned at the effective time, and Jon Adkins, previously the sole director and officer of the purchaser, became the sole director and is expected to serve as the sole officer of Repare.
Repare Therapeutics Inc. is having its common shares removed from listing and registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934. Nasdaq certifies it has met the requirements to file Form 25 for this delisting action.
Repare Therapeutics Inc. (RPTX) received a Schedule 13G reporting that Shay Capital LLC and Shay Capital Holdings LLC, both Delaware entities, beneficially own 2,870,141 common shares of the company, representing 6.7% of the outstanding common shares. The filing states that each filer has sole voting and sole dispositive power over these shares, with no shared voting or dispositive power. The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Repare Therapeutics, indicating a passive investment position.
Repare Therapeutics Inc. reported the results of a Special Meeting of shareholders held on January 16, 2026. Shareholders approved a special resolution for a plan of arrangement under Québec corporate law, under which Xeno Acquisition Corp. will acquire all of the issued and outstanding common shares, subject to the terms described in the company’s proxy statement.
The arrangement resolution passed with strong support, receiving 25,954,251 votes for and 58,162 against, with 4,811 abstentions, representing 99.76% of votes cast. Excluding votes required to be excluded under Multilateral Instrument 61-101, 25,879,894 votes for and 58,162 against, with 4,811 abstentions, also equaled 99.76% of votes cast.
Shareholders also approved, on an advisory non-binding basis, the compensation related to the transaction, with 25,846,791 votes for and 166,117 against. As a contingency if the arrangement were not approved or is later terminated, shareholders passed resolutions authorizing a potential voluntary liquidation and dissolution of the company and the possible appointment of KPMG LLP or another nationally recognized liquidator.
Repare Therapeutics is asking shareholders to approve a court‑supervised plan of arrangement under which Xeno Acquisition Corp., a subsidiary of XenoTherapeutics, will acquire all outstanding common shares. Each share would receive an estimated cash payment of approximately US$1.82 per common share, adjusted for the company’s cash, liabilities, transaction costs and a US$4,000,000 fee to the purchaser, plus one contingent value right (CVR) tied to specified future cash proceeds from existing partnerships, asset sales and certain tax reimbursements.
The special meeting will be held virtually on January 16, 2026, with approval of the arrangement requiring at least 66⅔% of votes cast plus a majority‑of‑the‑minority under Canadian rules. Directors, officers and key shareholders holding approximately 40% of eligible shares have agreed to support the deal. After closing, Repare expects to delist from Nasdaq, deregister under U.S. and Québec securities laws and ultimately wind up the business, with a fallback shareholder vote to liquidate if the arrangement is not completed.
Repare Therapeutics Inc. (RPTX) agreed to be acquired by non‑profit XenoTherapeutics, Inc. via a court‑approved plan of arrangement. Shareholders are expected to receive an estimated cash payment of about $1.82 per common share at closing, plus one non‑transferable contingent value right (CVR) per share that may pay additional cash based on future milestones under a CVR Agreement.
The company’s independent transaction committee and full board unanimously determined the arrangement is fair and in the best interests of shareholders and will recommend that shareholders vote in favor. The deal requires approval by at least 66⅔% of votes cast and a majority of minority shareholders, court approval under Québec law, and limits on dissenting shares, among other customary conditions. Officers and directors holding about 0.25% of outstanding shares have signed voting and support agreements in favor of the transaction.
Repare Therapeutics (RPTX) reported Q3 2025 results with net income of $3.3 million, led by $11.6 million of revenue from its Debiopharm license. Operating income was $1.1 million, supported by a $3.3 million gain from terminating a prior Debiopharm collaboration and $2.2 million of interest income. Basic and diluted EPS were $0.08.
Cash and cash equivalents were $72.8 million, with $39.8 million in marketable securities; total assets were $126.7 million and shareholders’ equity was $115.1 million. Year-to-date, the company recorded a net loss of $43.5 million and used $42.8 million in operating cash.
The company continued restructuring initiatives, incurring $1.8 million in Q3 and $8.5 million year-to-date. It also out‑licensed discovery platforms to DCx (9.99% equity stake and related rights) earlier in 2025.
Subsequent event: Repare signed a definitive agreement for acquisition by XenoTherapeutics. Holders will receive a cash payment per share based on cash at closing, plus one non‑transferable CVR per share; closing is subject to approvals and is expected in Q1 2026.
Repare Therapeutics reported a Regulation FD update announcing that the abstract from its Phase 1 LIONS trial of RP-1664 has been made available. The preliminary data in the abstract will be presented at the 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. The abstract, titled “Preliminary safety and antitumor activity of RP-1664, a first-in-class PLK4 inhibitor, as monotherapy in advanced solid tumors with and without TRIM37 amplification,” is posted on the Company’s website under Science > Scientific References.
The Company noted that information on its website is not incorporated by reference into other filings unless specifically stated.
Repare Therapeutics (RPTX) – Q2 FY25 10-Q highlights
- Revenue collapsed to $0.25 m (Q2 24: $1.07 m; 1H 24: $53.5 m, benefited from a $40 m Roche milestone now absent).
- Expense discipline: R&D cut 53 % and G&A down 28 %, driving total operating costs to $23.7 m (-38 % YoY). Restructuring charges of $3.4 m reflect a workforce reduction of ~75 % by Q4 25.
- Earnings: Net loss narrowed to $16.7 m (-$0.39/sh) from $34.8 m; 1H loss $46.8 m.
- Liquidity: Cash & marketable securities of $109.5 m; management guides funding runway to 2027.
- Strategic monetisation: Out-licensed discovery platforms to DCx ( $1 m cash, $3 m receivable, 9.99 % equity, $5.7 m gain booked ). Post-quarter, licensed lunresertib to Debiopharm for $10 m upfront plus up to $257 m milestones and single-digit royalties.
- Pipeline focus: resources concentrated on Phase 1 programs RP-3467 (POLAR) and RP-1664 (LIONS); topline safety/efficacy data expected Q4 25.
- Other: Bristol-Myers Squibb paid a $0.25 m option fee for an additional druggable target.
Cost reductions and asset deals offset revenue loss, but future value hinges on early-stage clinical read-outs.
Repare Therapeutics Inc. filed a current report to note that it issued a press release on August 8, 2025 detailing recent business highlights and its financial results for the three and six months ended June 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference into this report.
The company clarifies that the information in this report and the accompanying exhibits is not automatically incorporated into other Securities Act or Exchange Act filings unless specifically referenced, and that information on its website is not part of this disclosure.